Ignite Creation Date:
2025-12-24 @ 7:52 PM
Ignite Modification Date:
2026-01-05 @ 9:59 AM
Study NCT ID:
NCT05666804
Status:
COMPLETED
Last Update Posted:
2025-12-15
First Post:
2022-12-19
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy
Sponsor:
Novartis Pharmaceuticals
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Macular Polypoidal Choroidal Vasculopathy (PCV) | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Neovascular age-related macular degeneration | View |
| None | polypoidal choroidal vasculopathy | View |
| None | anti-vascular endothelial growth factor | View |
| None | brolucizumab | View |
| None | personalized regimen | View |
| None | treat-and-extend | View |
| None | Retina damage | View |
| None | Retinal disease | View |
| None | Vascular disease | View |
| None | Eye disease | View |
| None | blind spot | View |
| None | fluid leak into or under the retina | View |
| None | blood leak into or under the retina | View |
| None | macular polypoidal choroidal vasculopathy (PCV) | View |
| None | PCV | View |